TGTX Nasdaq Pharmaceutical Preparations Financials FY2016βFY2025
Tg Therapeutics, Inc. had $616M of revenue in fiscal 2025, up 87.3% on the year before. Over five years, revenue changed +426.7% a year on average.
Last close Β· Oct 23, 2026
$54.17
1.9%Hi! I read Tg Therapeutics, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+87.3%
Yes. Sales grew 87.3% last year.
Does it make a profit?
72.6%
Yes. It keeps 72.6% of every sale as profit.
Does profit turn into cash?
β4.1%
No. It spent more cash than it brought in.
Is debt under control?
0.8x
Yes. It could repay its debt with 0.8 years of operating profit.
How healthy are the accounts?
4 / 9
Mixed. It passes 4 of 9 health tests.
How is the share priced?
19.8x
One share costs 19.8 times its yearly profit per share.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
KIRA Β· Tg Therapeutics, Inc. had $616M of revenue in fiscal 2025, up 87.3% on the year before. Over five years, revenue changed +426.7% a year on average. Its operating margin was 20.0%, up 7.3Β pts: of every 100 in sales, about 20 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Tg Therapeutics, Inc. made $447M of net profit in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$25.0M in fiscal 2025, β4.1% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· In the last 12 months, insiders sold $0.4M of shares on the open market and bought none.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.4M
2 insiders
Of sales under plans
0%
$0.0M
Can it carry its debts, and how well does it use its money?
KIRA Β· Tg Therapeutics, Inc. owes $104M more than it holds in cash, about 0.8 years of operating profit.
Cash, debt and the ratios that show how comfortably Tg Therapeutics, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $315M | $162M | $218M | $311M | $142M |
| Debt incl. finance leases | $67.8M | $71.1M | $100M | $244M | $246M |
| Net debt / EBITDA | β | β | β5.6x | β1.6x | 0.8x |
| Debt / equity | 0.3x | 1.2x | 0.6x | 1.1x | 0.4x |
| Interest coverage | β61.2x | β21.4x | 1.6x | 1.7x | 4.6x |
| Current ratio | 5.1x | 3.2x | 5.9x | 6.2x | 4.1x |
| Quick ratio | 5.1x | 3.2x | 5.2x | 5.0x | 3.3x |
| Total assets | $380M | $194M | $330M | $578M | $1.1B |
| Total liabilities | $142M | $135M | $169M | $355M | $415M |
| Shareholders' equity | $237M | $58.6M | $161M | $222M | $648M |
| Net debt (β = net cash) | β$247M | β$90.5M | β$117M | β$66.6M | $104M |
KIRA Β· Its return on capital was 16.4%: every 100 invested in the business earned about 16 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Tg Therapeutics, Inc. passes 4 of 9 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 3 / 7 | 2 / 7 | 2 / 8 | 4 / 8 | 2 / 8 | 2 / 9 | 6 / 9 | 3 / 9 | 4 / 9 |
| Accruals ratio | β30.4% | β32.5% | β49.2% | β32.5% | β16.5% | β10.4% | β16.6% | 16.9% | 14.1% | 57.5% |
| Altman Z'' | β17.69 | β13.35 | β31.04 | β18.06 | 2.58 | β11.18 | β28.94 | β8.68 | β2.08 | 2.04 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $0.2M | $0.2M | $0.2M | $0.2M | $0.2M | $6.7M | $2.8M | $234M | $329M | $616M |
| Gross profit | β | β | β | β | β | $5.9M | $2.5M | $220M | $291M | $516M |
| Research and development | $69.2M | $103M | $159M | $154M | $166M | $223M | $125M | $76.2M | $94.3M | $160M |
| Operating income | β$79.0M | β$119M | β$174M | β$169M | β$274M | β$345M | β$218M | $20.6M | $41.9M | $123M |
| Interest expense | β | $0.8M | $0.9M | $5.3M | $6.3M | $5.6M | $10.2M | $12.6M | $24.0M | $26.7M |
| Pretax income | β$78.3M | β$0.1M | β$0.2M | β$0.2M | β$0.3M | β$348M | β$224M | $13.1M | $25.6M | $107M |
| Income tax | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.4M | $2.2M | β$340M |
| Net income | β$78.3M | β$118M | β$173M | β$173M | β$279M | β$348M | β$224M | $12.7M | $23.4M | $447M |
| Diluted EPS | β$1.60 | β$1.91 | β$2.30 | β$1.96 | β$2.42 | β$2.63 | β$1.65 | $0.09 | $0.15 | $2.77 |
| Diluted shares | 0.05B | 0.06B | 0.08B | 0.09B | 0.12B | 0.13B | 0.14B | 0.15B | 0.16B | 0.16B |
| Cash flow | ||||||||||
| Cash from operations | β$61.6M | β$93.8M | β$129M | β$133M | β$215M | β$296M | β$176M | β$31.4M | β$40.5M | β$24.8M |
| Capital expenditure | $0.3M | $0.0M | $0.1M | $0.1M | $0.4M | $0.4M | $0.0M | $0.0M | $0.0M | $0.2M |
| Free cash flow | β$61.9M | β$93.8M | β$129M | β$133M | β$215M | β$296M | β$176M | β$31.4M | β$40.6M | β$25.0M |
| Depreciation and amortization | $0.1M | $0.1M | $0.1M | $0.1M | $0.2M | $0.3M | $0.3M | $0.2M | $0.1M | $0.1M |
| Stock-based compensation | $7.5M | $15.9M | $12.9M | $11.3M | $80.3M | $61.3M | $44.7M | $37.9M | $42.5M | $64.7M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $44.9M | $84.7M | $68.9M | $140M | $605M | $315M | $162M | $218M | $311M | $142M |
| Total debt | β | β | $0.0M | $29.0M | $29.9M | $67.8M | $71.1M | $100M | $244M | $246M |
| Current assets | $50.9M | $93.3M | $79.0M | $149M | $612M | $331M | $168M | $318M | $566M | $631M |
| Current liabilities | $16.9M | $28.0M | $38.9M | $84.4M | $87.6M | $65.4M | $53.2M | $53.7M | $90.7M | $154M |
| Inventory | β | β | β | β | β | β | $0.0M | $39.8M | $110M | $126M |
| Property and equipment, net | $0.3M | $0.2M | $0.3M | $0.3M | $0.5M | $0.6M | $0.3M | $0.1M | β | β |
| Goodwill | $0.8M | $0.8M | $0.8M | $0.8M | $0.8M | $0.8M | $0.8M | $0.8M | β | β |
| Total assets | $54.8M | $97.4M | $83.6M | $163M | $626M | $380M | $194M | $330M | $578M | $1.1B |
| Total liabilities | $18.9M | $30.4M | $59.6M | $124M | $106M | $142M | $135M | $169M | $355M | $415M |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | β | β | β | β | β |
| Shareholders' equity | $35.9M | $67.0M | $24.0M | $38.6M | $519M | $237M | $58.6M | $161M | $222M | $648M |
| Margins | ||||||||||
| Gross margin | β | β | β | β | β | 88.2% | 90.5% | 94.0% | 88.3% | 83.7% |
| Operating margin | β51,953.3% | β78,100.0% | β114,736.8% | β111,220.4% | β179,996.1% | β5,154.3% | β7,839.0% | 8.8% | 12.7% | 20.0% |
| EBITDA margin | β51,911.8% | β78,046.1% | β114,678.9% | β111,154.6% | β179,892.1% | β5,150.1% | β7,828.1% | 8.9% | 12.8% | 20.0% |
| Net margin | β51,482.2% | β77,944.7% | β114,132.9% | β113,730.9% | β183,803.3% | β5,204.1% | β8,036.3% | 5.4% | 7.1% | 72.6% |
| FCF margin | β40,744.1% | β61,685.5% | β84,878.3% | β87,458.6% | β141,357.9% | β4,425.7% | β6,326.2% | β13.4% | β12.3% | β4.1% |
| Returns | ||||||||||
| Return on capital | β | β | β | β | β | β | β | 46.1% | 24.6% | 16.4% |
| Return on capital employed | β208.3% | β171.0% | β389.6% | β215.2% | β50.8% | β109.7% | β155.5% | 7.5% | 8.6% | 13.6% |
| Return on equity | β218.2% | β230.4% | β381.2% | β551.9% | β100.1% | β92.0% | β151.4% | 11.6% | 12.2% | 102.8% |
| Return on assets | β142.8% | β155.7% | β191.7% | β140.2% | β70.8% | β69.3% | β78.1% | 4.8% | 5.2% | 54.5% |
| Return on tangible equity | β223.1% | β179.0% | β746.6% | β457.1% | β53.9% | β147.3% | β387.3% | 7.9% | 10.5% | 69.0% |
| Growth | ||||||||||
| Revenue growth | β | 0.0% | 0.0% | 0.0% | 0.0% | 4,300.7% | β58.4% | 8,290.0% | 40.8% | 87.3% |
| Net income growth | β | β | β | β | β | β | β | β | 84.5% | 1,812.4% |
| EPS growth | β | β | β | β | β | β | β | β | 66.7% | 1,746.7% |
| Share count change | β | 26.6% | 21.6% | 17.1% | 30.5% | 14.6% | 2.4% | 9.7% | 8.0% | 0.7% |
| Financial health | ||||||||||
| Net debt / EBITDA | β | β | β | β | β | β | β | β5.6x | β1.6x | 0.8x |
| Debt / equity | β | β | 0.0x | 0.8x | 0.1x | 0.3x | 1.2x | 0.6x | 1.1x | 0.4x |
| Interest coverage | β | β140.5x | β198.9x | β32.0x | β43.2x | β61.2x | β21.4x | 1.6x | 1.7x | 4.6x |
| Current ratio | 3.0x | 3.3x | 2.0x | 1.8x | 7.0x | 5.1x | 3.2x | 5.9x | 6.2x | 4.1x |
| Quick ratio | 3.0x | 3.3x | 2.0x | 1.8x | 7.0x | 5.1x | 3.2x | 5.2x | 5.0x | 3.3x |
| Capital allocation | ||||||||||
| Capex / revenue | 226.3% | 1.3% | 59.2% | 86.2% | 234.9% | 6.0% | 0.5% | 0.0% | 0.0% | 0.0% |
| Stock comp / revenue | 4,934.2% | 10,460.5% | 8,477.6% | 7,457.2% | 52,821.7% | 916.0% | 1,603.7% | 16.2% | 12.9% | 10.5% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 3.0 | 2.0 | 2.0 | 4.0 | 2.0 | 2.0 | 6.0 | 3.0 | 4.0 |
| Altman Z'' | β17.7 | β13.4 | β31.0 | β18.1 | 2.6 | β11.2 | β28.9 | β8.7 | β2.1 | 2.0 |
| Accruals ratio | β30.4% | β32.5% | β49.2% | β32.5% | β16.5% | β10.4% | β16.6% | 16.9% | 14.1% | 57.5% |
Source: SEC EDGAR XBRL filings (CIK 0001001316). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
